Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian pharmaceutical firm Knight Therapeutics has signed an exclusive agreement with Akorn for the exclusive distribution of AzaSite (azithromycin ophthalmic solution) in Canadian markets.
Subscribe to our email newsletter
As part of the deal, Knight will be responsible or handling all regulatory and commercial activities for AzaSite in Canada.
AzaSite 1% is a prescription sterile eye drop solution indicated for use in adult and pediatric patients aged one year and older for topical treatment of bacterial conjunctivitis.
Marketed by Akorn in the US, AzaSite was approved by the US Food and Drug Administration in 2007.
The Canadian ophthalmic antibiotic market reached about $27m in sales in 2014 and when launched, AzaSite is expected to be the first ophthalmic azithromycin product to be available in Canada, according to IMS Health.
Knight president and CEO Jonathan Ross Goodman said: "We are excited to work with Akorn to bring a new ophthalmic antibiotic to the market and add a differentiated product to our growing ophthalmology portfolio.
"We believe that providing another tool in physicians’ armamentarium with a convenient and unique dosing profile is something that will resonate with both patients and physicians."
Conjunctivitis is an inflammation of the transparent membrane covering the eyelid and part of the eyeball and often caused by a bacterial or viral infection.